Literature DB >> 24825498

Factors affecting the spontaneous expulsion of the levonorgestrel-releasing intrauterine system.

Jina Youm1, Hyun Ju Lee1, Seul Ki Kim2, Hoon Kim1, Byung Chul Jee3.   

Abstract

OBJECTIVE: To estimate the incidence of, and identify risk factors for, spontaneous expulsion of the levonorgestrel-releasing intrauterine system (LNG-IUS).
METHODS: Pre-insertion characteristics for 481 women who received the LNG-IUS at a single institution in the Republic of Korea between 2003 and 2011 were analyzed retrospectively. The median duration of follow-up was 13.4 months. Kaplan-Meier plots were constructed to estimate the time to occurrence of spontaneous expulsion in multiple subgroups.
RESULTS: The overall crude incidence of spontaneous LNG-IUS expulsion was 9.6%. The cumulative incidence was 7.9%, 9.1%, and 9.6% at 1, 2, and 3 years, respectively. It was significantly higher in women with adenomyosis (9.1%, 10.6%, and 11.1%) or uterine leiomyoma (14.5%, 15.8%, and 15.8%) than in those with a normal uterus (3.6%, 4.1%, and 4.6%) (P=0.008). Women with heavy menstrual bleeding (11.0%, 12.7%, and 13.4%), dysmenorrhea (8.1%, 9.0%, and 10.0%), or pre-insertion receipt of gonadotropin-releasing hormone agonists (13.3%, 16.0%, and 17.3%) also had higher cumulative incidences than those without these conditions (P<0.05). Most (84.5%) women with a spontaneous expulsion chose to discontinue the device.
CONCLUSION: Clinicians need to be aware of the risk factors for spontaneous LNG-IUS expulsion because this can lead to a discontinuation of its use.
Copyright © 2014 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Adenomyosis; Heavy menstrual bleeding; Intrauterine device expulsion; Levonorgestrel; Risk factors; Uterine leiomyoma

Mesh:

Substances:

Year:  2014        PMID: 24825498     DOI: 10.1016/j.ijgo.2014.02.017

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  6 in total

1.  [Efficacy and adverse effects of levonorgestrel-releasing intrauterine system in treatment of adenomyosis].

Authors:  Lifeng Zhang; Hui Yang; Xinmei Zhang; Zhengyun Chen
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-04-25

Review 2.  Heavy menstrual bleeding diagnosis and medical management.

Authors:  Intira Sriprasert; Tarita Pakrashi; Thomas Kimble; David F Archer
Journal:  Contracept Reprod Med       Date:  2017-07-24

3.  Association of the Timing of Postpartum Intrauterine Device Insertion and Breastfeeding With Risks of Intrauterine Device Expulsion.

Authors:  Mary Anne Armstrong; Tina Raine-Bennett; Susan D Reed; Jennifer Gatz; Darios Getahun; Juliane Schoendorf; Debbie Postlethwaite; Michael J Fassett; Jeffrey F Peipert; Catherine W Saltus; Maqdooda Merchant; Amy Alabaster; Xiaolei Zhou; Laura Ichikawa; Jiaxiao M Shi; Vicki Y Chiu; Fagen Xie; Shannon Hunter; Jinyi Wang; Mary E Ritchey; Giulia Chillemi; Theresa M Im; Harpreet S Takhar; Federica Pisa; Alex Asiimwe; Mary S Anthony
Journal:  JAMA Netw Open       Date:  2022-02-01

4.  Effect of modified levonorgestrel-releasing intrauterine system in human adenomyosis with heavy menstrual bleeding.

Authors:  Hong Yang; Shengtan Wang; Xiaoyan Fu; Ruihong Lan; Humin Gong
Journal:  J Obstet Gynaecol Res       Date:  2021-10-21       Impact factor: 1.697

5.  Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study.

Authors:  Qing Li; Yan Ding; Xu-Yin Zhang; Wei-Wei Feng; Ke-Qin Hua
Journal:  J Int Med Res       Date:  2018-03-19       Impact factor: 1.671

6.  Comparing options for females seeking permanent contraception in high resource countries: a systematic review.

Authors:  Rebecca Gormley; Brian Vickers; Brooke Cheng; Wendy V Norman
Journal:  Reprod Health       Date:  2021-07-20       Impact factor: 3.223

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.